Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1Phase 1 1

Status

Recruiting 32Unknown 22Completed 15Not yet recruiting 12Active not recruiting 10Terminated 8Approved for marketing 3Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Breast 8Gastrointestinal 1

Conditions

Breast Neoplasms 1127Neoplasms 982Carcinoma, Non-Small-Cell Lung 900Prostatic Neoplasms 594Neoplasm Metastasis 528Leukemia, Myeloid, Acute 513Colorectal Neoplasms 491Lung Neoplasms 487Melanoma 485Multiple Myeloma 477Pancreatic Neoplasms 385Lymphoma 369Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 346Leukemia 339Leukemia, Lymphocytic, Chronic, B-Cell 321Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 273Carcinoma, Hepatocellular 261Glioblastoma 249Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 242Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Trastuzumab 4pertuzumab 2Docetaxel 2palbociclib 1Protons 1Paclitaxel 1Letrozole 1Fulvestrant 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Terminated × HER2-positive Breast Cancer × Clear all
NCT03738553 2026-05-04

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

University of Washington

Terminated
13 enrolled
Breast

HER2-positive Breast Cancer

NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

National Cancer Centre, Singapore

Phase 2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT01722890 2025-07-08

CharactHer. ICORG 12-09, V3

Cancer Trials Ireland

Terminated
130 enrolled
Breast

HER2-positive Breast Cancer

NCT05511844 2025-07-04

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Orum Therapeutics USA, Inc.

Phase 1 Terminated
25 enrolled
Breast

HER2-positive Breast Cancer

NCT05555251 2024-12-16

CONTRAST

BioInvent International AB

Phase 1/2 Terminated
18 enrolled
BreastGastrointestinal

HER2-positive Breast Cancer

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

University of Kansas Medical Center

Phase 1/2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated
8 enrolled 1 chart
Breast

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Western Regional Medical Center

Phase 1/2 Terminated
4 enrolled 1 chart
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡